LIPOCINE INC.

LPCN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-9.6M $8.4K $-16.4M $-10.8M $-634.4K $-21.0M $-13.0M $-11.7M
Depreciation & Amortization $60.8K $41.1K $28.7K $9.5K $380 $3.6K $15.4K $18.6K
Depreciation $61.0K $41.0K $29.0K $9.5K $400 $4.0K
Amortization
Stock-Based Compensation $242.5K $408.6K $654.4K $636.1K $603.9K $1.4M $1.0M $1.5M
Net Cash from Operating Activities $-9.8M $-1.2M $-11.9M $-12.0M $-4.4M $-15.3M $-11.7M $-12.1M
Investing Activities
Capital Expenditures $90.1K $13.2K $133.8K $7.6K $0
Business Acquisitions
Net Cash from Investing Activities $5.9M $2.4M $13.1M $14.3M $-43.8M $3.9M $3.0M $11.3M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $2.9M $209.3K $404.6K $-2.1M $26.9M $20.9M $10.3M $10.7M
Net Change in Cash $-1.0M $1.4M $1.6M $197.9K $-21.3M $9.5M $9.9M
Free Cash Flow $-1.3M $-11.9M $-12.1M $-4.4M $-12.1M
← Newer Page 1 of 2 Older →